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Abstract: The in vitro antithrombotic properties of polar lipid constituents of malted grain (MG),
pelleted hops (PH), brewer’s spent grain (BSG), spent hops (SH), wort, and bottled beer from the
same production line were assessed in human platelets. The total lipids (TL) were extracted according
to the Bligh and Dyer method and further separated into the total neutral lipids (TNL) and total polar
lipids (TPL) extracts by counter-current distribution. The TL, TNL, and TPL extracts of all samples
were assessed for their ability to inhibit platelet-activating factor (PAF) and thrombin-induced human
platelet aggregation. The raw materials, by-products, wort, and beer lipid extracts all exhibited
antithrombotic properties against PAF and thrombin. However, the beer TPL exhibited the lowest IC50
values against PAF-induced (7.8 ± 3.9 µg) and thrombin-induced (4.3 ± 3.0 µg) platelet aggregation
indicating that these polar lipids were the most antithrombotic. The lipid extracts tended to be more
bioactive against the thrombin pathway. The fatty acid content of all the TPL extracts were assessed
using GC-MS. The fatty acid composition of the most bioactive TPL extracts, the wort and the beer,
shared similar fatty acid profiles. Indeed, it was noted that fermentation seems to play a role in
increasing the antithrombotic properties of polar lipids against PAF and thrombin by moderately
altering the polar lipid fatty acid composition. Furthermore, the use of brewing by-products as a
source of functional cardioprotective lipids warrants further investigation and valorisation.
Keywords: fermentation; beer; brewer’s spent grain; hops; polar lipids; platelet-activating factor;
thrombin; cardiovascular disease; antithrombotic
1. Introduction
Cardiovascular diseases (CVD) are the leading cause of mortality globally, where diet and lifestyle
are key modifiable risk factors [1]. The harmful effects of alcohol consumption have been well
established, as excessive alcohol consumption has been linked to several chronic diseases, including
cancer [2,3]. However, moderate alcohol consumption (up to 16 g alcohol/day) has been associated
with cardiovascular health benefits, including reduced fasting glucose and blood insulin sensitivity
versus non-alcoholic beer in healthy men [4]. Indeed, consumption of 1–2 alcoholic beverages/day is
associated with reduced fibrinogen levels, reduced platelet aggregation, and an increase in high-density
lipoprotein (HDL). These effects have mostly been attributed to the ethanol content and the presence of
phenolic compounds [5–7]. Epidemiological studies demonstrate that moderate alcohol consumption
reduced cardiovascular risk factors, morbidity, and mortality following a dose-effect relationship that
is characterised by a J-shaped curve [6].
Atherosclerosis is the first step in the development of CVD [1]. Platelet-activating factor (PAF)
is a potent platelet agonist and inflammatory mediator implicated in the onset and progression
Foods 2019, 8, 171; doi:10.3390/foods8050171 www.mdpi.com/journal/foods
Foods 2019, 8, 171 2 of 17
of atherosclerosis [8,9]. PAF and PAF-like molecules carry out their functions by binding to the
PAF-receptor (PAF-R), which is expressed in various cell types, including platelets, endothelial
cells, neutrophils, and macrophages [1]. Activation of the PAF-R leads to the induction of multiple
inflammatory pathways and platelet activation [1].
Thrombin is another important mediator of platelet activation [10]. Thrombin is a serine protease
that participates in the coagulation cascade, activating factors V, VIII, XI, and XII, converting fibrinogen
to fibrin, and activating other cell types [10,11]. Both PAF and thrombin are produced during
coagulation and inflammation and play a crucial role in platelet activation and thrombus formation
via G protein-coupled receptors [12]. Previously these two pathways were considered independent.
However, recent evidence suggests that there is a crosstalk between coagulatory and inflammatory
pathways during pathological processes, whereby inflammation leads to platelet activation in a
reciprocal fashion [13]. Considering the important roles that PAF and thrombin hold at the nexus
of coagulation and inflammation, antiplatelet and anti-inflammatory therapeutic and preventative
strategies are required to prevent the development of chronic diseases such as CVD. Within this concept,
several compounds of natural origin [1] can inhibit the binding of PAF to the PAF-R, which ameliorates
the PAF inflammatory and prothrombotic response. Notably, polar lipid constituents of ale, lager, and
stout have exhibited potent anti-PAF and antithrombotic properties [14]. However, little is known
about the origin of these beer-derived antithrombotic polar lipid microconstituents and their effects
against the thrombin pathway.
Beer is the most consumed alcoholic beverage globally. The raw materials used in beer production
influence the different characteristics and properties of the beer [4]. Beers are produced from malted
barley, water, hops (Humulus lupulus), and yeast (Saccharomyces cerevisiae). Barley (Hordeum vulgare)
contains 2–4% (dry weight) lipid depending on various factors [15]. Commercial malts can contain up
to 3.4% lipid. Approximately 70–90% of the fatty acid content of the barley and malt is triglycerides,
10–20% are sterol compounds, and approximately 10% are free fatty acids. The free lipid composition of
the barley grain is approximately 68–75% neutral lipids, 7–26% glycolipids, and 9–18% phospholipids
depending on the cultivar [16]. Germination of the barley and the mashing process can lead to the loss
of lipid due to the release of fatty acids via the hydrolysis of triglycerides, which are then metabolised.
The resulting fatty acids, mono-, and diglycerides do not tend to accumulate in the malt, and thus are
not found in significant quantities in the finished product [17]. Moreover, several phospholipids can
form complexes with amylose in starch before the brewing process [18]. A significant proportion of the
lipid content is lost to the spent grains generated during the brewing process, and so the wort and beer
contains low levels of lipid [19]. There is only a trace amount of lipid that remains in the final beer
product, which are generally considered undesirable due to their impact on the formation of haze,
the stability of beer foam, and the development of unfavourable flavours during conditioning [17,20].
Brewing yeasts also have the capacity to synthesise and alter several lipid species, including
phospholipids and polyunsaturated fatty acids (PUFA) [21], which play a crucial role in the metabolic
pathways and regulation of lipid catabolism and anabolism in yeast [17]. Furthermore, there is an
increased concentration of stearic, cis-oleic, and linolenic acid in the wort as a result of endogenous lipase
activity that releases free fatty acids from triglycerides and phospholipids in the mashing and malting
process [21,22]. In addition, the composition of the malt and lauter turbidity can lead to the formation
of triglycerides, diglycerides, monoglycerides, free fatty acids, phospholipids, and sphingolipids
during the fermentation process [23].
The unfortunate consequence of beer production is the generation of brewing wastes and
by-products, which are a significant environmental challenge, but may be valorised for the development
of novel products [24]. Industrial-scale food processing by-products are increasingly being viewed
as potential sources of bioactive ingredients. One such example in the brewing industry by-product
previously sent to landfill is BSG [25], which is now primarily used for animal feed. The lipid content
of BSG is approximately 10.0–13.5% (w/w of BSG samples) [26], where it is estimated that 9.1% of the
total lipids are phospholipids [27].
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Considering little is known about the fatty acid composition of bioactive polar lipid microconstituents
of beer or brewing by-products, the aim of this study was to assess the antithrombotic properties
and fatty acid composition of lipid extracts sampled at various stages of the brewing process, from
the brewing raw materials (malted grain and hops), the by-products (BSG and spent hops), the wort,
and the finished beer product from a commercial beer produced in Ireland.
2. Materials and Methods
2.1. Chemicals and Reagents
All glassware, chemicals, and solvents were of analytical grade and purchased from Fisher
Scientific Ireland Ltd. (Dublin, Ireland). All reagents used for platelet aggregation, including bovine
serum albumin (BSA), standard PAF, and standard thrombin, were high purity and purchased
from Sigma-Aldrich (Wicklow, Ireland). Blood consumables, including needles (20G) and 8.2 mL
sodium citrate S-monovettes, were purchased from Sarstedt Ltd. (Wexford, Ireland). For GC-MS,
a pre-derivatised Supelco™ 37-component FAME standard mix, pre-derivatised heptadecanoic acid, and
pre-derivatised heneicosanoic acid was purchased from Sigma-Aldrich (Wicklow, Ireland). All platelet
aggregometry consumables were purchased from Labmedics LLP (Abingdon on Thames, UK).
All GC-MS consumables were purchased from Apex Scientific Ltd. (Kildare, Ireland).
2.2. Beer Production and Samples Assessed
The beer, wort, raw materials, and brewing by-products used for this study were obtained from
the Munster Brewery facility (Youghal, Co. Cork, Ireland). The samples assessed in this study were
pelleted hops (PH), spent hops (SH), malted grains (MG), brewer’s spent grains (BSG), wort, and the
beer itself. All the raw materials, wort, and by-products obtained for this study correspond to the
same batch and production line of the beer that was produced for and tested in this study. The beer
is an organically produced Irish red ale for commercial sale under the name ‘12 Towers’ brewed in
accordance with organic standards certified by the Irish Organic Association.
The beer production is described in brief as follows. Of the malts used, approximately 90% of the
overall malt was organic pale ale malt (Maris Otter malt) was kiln dried at 90–95 ◦C to produce the
base malt of the beer with a maximum moisture content of 4.5% and a European Brewing Convention
(EBC) colour scale between 7 and 10 (Castle Malting Ltd., Beloeil, Belgium). A small amount of organic
roasted barley (approximately 10% of the total malt used), which was kiln dried to 230 ◦C that produced
a roasted grain that had a maximum moisture content of 4.5% and was a colour rating between
1000–1400 EBC. Once milled by the brewery, the grains were mashed in the mash tun. To formulate the
wort, 4 L of water was added per kg of crushed grain, which was steeped in the mash tun at 66 ◦C for
60 min. This process activated the α- and β-amylase enzymes (among others) that convert the starch
to simple sugars to produce the so-called sweet wort. At the end of the mash, the lautering process
begins by raising the temperature to 77–79 ◦C to denature the enzymes by adding heated sparge water,
which also weakens the gravity of the wort runoff. This process takes approximately 3–4 h. Once
Lautering was complete a sample of the BSG was stored. A brewer’s hydrometer was used to measure
the original gravity (OG) of the first running, which can be as high as 1.080 and also subsequently to
confirm that the kettle wort is at an acceptable gravity prior to commencing boiling. The OG prior to
fermentation was 1.042 and final gravity (FG) after fermentation was 1.010. These hydrometer readings
are used to measure the fermentable and unfermentable substances the in wort before and during
fermentation and to calculate the beers final alcoholic content (alcohol by volume or ABV) when OG is
compared to the FG. Runnings from the mash tun were transferred to the kettle and once complete,
the wort was heated to 100 ◦C and brought to the boil for 1 h, which sterilised the wort, denatured any
remaining enzymes, and allowed for caramelisation of the sugars for flavour enhancement.
At the start of the boil a specific amount of organic pelleted hops (PH: Organic Goldings Hops,
Charles Faram Ltd., Worcester, UK) was calculated based on flavour rating (approximately 200 g/hL)
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of the hops for each batch and was added to the kettle, which was boiled for a further hour. These
pelleted hops are strobiles from the female hop plant that are air-dried and pelleted, and thus extremely
concentrated in comparison to fresh strobiles. Thereafter, the wort underwent whirlpooling a rapid
cooling process by being passed through a heat exchanger, which reduced the temperature of the wort
to 20 ◦C. A sample of the wort was taken at this point. After whirlpooling when the wort had been
moved on in the process, a sample of the SH was taken. The SH sample in reality is not purely hops,
it is also known as the trub, which consists of primarily hop debris (10–20%), but is also a source of
sedimented protein (50–70%), phenolic compounds (5–10%), carbohydrates (4–8%), and fatty acids
(1–2%) originating from the hops and residues from the barley processing [28]. The cooled wort was
transferred to the primary fermenter and was held at 20 ◦C. At this temperature, the yeast, a dehydrated
Saccharomyces cerevisiae (Nottingham High Performance Ale Yeast, Lallemand Inc., Burton upon Trent,
UK) was diluted in sterilised water and pitched (80–100 g per hL) into the filled fermentation tank.
This is a top fermenting yeast that is commonly used to produce a wide variety of beers, including
ambers, porters, stouts, and pale ales. The fermentation ran for four days. Following fermentation,
a conditioning period was allowed to take place at 12 ◦C for approximately 7 days. After conditioning,
the beer underwent cold crashing. In this process, the temperature of the conditioned beer is reduced
to between 0–2 ◦C over 3–4 days. The process of cold crashing promotes the flocculation of yeast,
which sink to the bottom of the tank due to gravity and are removed, thus increasing the clarity of the
beer naturally without the need for additives. Indeed, cold crashing is also desirable due to its effects
on other suspended particles, such as tannins, polyphenols, and proteins that can also flocculate and
settle at the bottom of the tanks, preventing the undesirable phenomenon of chill haze. Once cold
crashing was complete, the beer was bottled with a 2 g of 100% fermentable organic dextrose (Charles
Faram Ltd., Worcester, UK) added to each bottle to encourage carbonation by any remaining yeast in
the beer. The carbonation process takes approximately 14 days at room temperature until an optimal
level of 2.2–2.5 volumes of CO2 was achieved. Once complete the bottles were placed in cold storage
(0–4 ◦C) for a short period of time until ready to distribute.
The finished bottled beer product, the wort, and the various by-products collected were placed
in airtight containers and transported to the laboratory. The beer and wort were extracted on the
day of arrival to the laboratory and the other by-products and raw materials were stored at −20 ◦C
for a maximum of three weeks until required for extraction and analysis. All samples were taken in
triplicate from different batches of the beer production process. The brewing process and sampling
points are outlined in Figure 1.
2.3. Extraction and Isolation of the TL, TNL, and TPL Extracts
The total lipids (TL) of all samples were extracted in triplicate according to the Bligh and Dyer [29]
method. Notably, the lipids from the brewing materials, by-products, wort, and beer were extracted
from different batches of production. A tenth of each TL was stored under nitrogen at −20 ◦C and the
remaining lipid was subjected to counter-current distribution as previously described [14] to obtain
the total polar lipid (TPL) and the total neutral lipid (TNL) extracts. All extracts were stored under
nitrogen at −20 ◦C until required for a maximum of 6 months as previously described [14].
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active thrombin were diluted in appropriate amounts of physiological saline to obtain solutions of 
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2.4. Platelet Aggregation Assay
The in vitro assessment of PAF and thrombin-induced platelet aggregation was carried out as
previously described [14,30]. In brief, healthy human volunteers (N = 12) free from any form of
antiplatelet therapy gave informed written consent and all protocols were executed in accordance
with the Declaration of Helsinki following ethical approval by the University of Limerick Ethics
Committee. Participants provided 50 mL or blood following an overnight fast (>8 h). The blood was
drawn via venepuncture of the median cubital vein using a 20G needle into evacuated sodium citrate
S-monovettes via the aspiration method (0.106 mol/L in a 1:10 ratio of citrate to blood). To obtain
the platelet-rich plasma, S-monovettes were immediately centrifuged at 180× g for 18 min at 24 ◦C
(Eppendorf 5702 R, Eppendorf Ltd, Stevenage, UK). A second centrifugation at 1500× g for 20 min
at 24 ◦C was carried out to btain the platelet-poor plasma (PPP). The PRP was standar ised to
500,000 platelets µL−1 using a Shimadzu UV-1800 spectrophotometer (Kyoto, Japan), prior to analysis
o a Chronolog-490 two channel platelet aggregometer (Chron l g, Havertown, PA, USA), coupled
to t e specialised AGGRO/LINK software package. Prior to testing, lipid samples and standard PAF
were dissolved in a solution of BSA-saline (2.5 mg BSA/mL sali e), while aliquots of stock solutions of
active thrombin were diluted in appropriate amounts of physiological saline to obtain solutions of
active thrombin with a final concentration in the aggregometer cuvette, ranging from 0.01 mU/mL NIH
(National Institute of Health). The final concentration of PAF in the cuvette ranges from 1–5 × 10−8 M.
Then, 250 µL of P P was added to an aggregometer cuvette at 37 ◦C with stirring at 1000 rpm. The PRP
was calibrated using the PPP as a blank. PAF and thrombin were added to the cuvettes in order to
induce maxim m reversible aggregation in the absence of any lipid sam les. For each lipid sample,
the mass of lipid required to inhibit 50% the PAF or thrombin-induced aggregation was calculated.
Subsequently, the IC50 was calculated as previously described [14,30]. Platelet aggregation experiments
for each TPL, TNL, and TL extract was carried out in triplicate against both PAF and thrombin as
previously described [30,31].
2.5. Gas Chromatography-Mass Spectrometry
The preparation and analysis of the fatty acid methyl esters (FAME) were carried out in triplicate
using 35 mg of the TPL samples of all samples as previously described [14]. Briefly, FAMEs were
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derivatised using a 0.5 M KOH CH3OH 90% solution and extracted with n-hexane. The analysis was
carried out using the internal standard method (Heneicosanoic acid—21:0) as previously described
for other beverage analysis [14]. A five-point calibration curve was prepared using heneicosanoic
acid (21:0 500 ppm injections) and five solutions of heptadecanoic acid (17:0—50, 100, 200, 400, and
800 ppm) methyl ester standards. Five 1 µL injections of each solution were analysed using a Varian
410-GC coupled to a Varian 210-MS equipped with a split/splitless injector (Agilent Technologies,
Santa Clara, CA, USA). Separation of the FAME was conducted on an Agilent J&W DB-23 fused silica
capillary column (60 m, ‘0.25 mm i.d.’ 0.25 µm f.t.; Agilent Technologies). The ratio of the mean
17:0 to that of the internal standard (21:0) was used as the y-axis variable, while the concentration
(ppm) of 17:0 was used as the x-axis variable of the calibration curve. The equation describing the
curve was: y = 0.0041x + 0.12, with a R2 = 0.9969, where the ratio of the area of the analyte peak to
that of the internal standard represents the y value for the equation of the calibration curve and the
x value represents the analyte concentration of a selected fatty acid in the lipid sample. The injector
temperature of the Varian 410-GC and 210-MS was set at 230 ◦C with a split ratio of 1:20. The carrier
gas was high purity helium with a liner flow rate of 1 mL/min. The oven temperature was initially
programmed to 100 ◦C for 5 min, raised to 240 ◦C at 3 ◦C/min, and finally held isothermal at 240 ◦C for
10 min. Identification of FAME was achieved using a pre-derivatised standard 37-component FAME
sample mix and comparison of the retention times and mass spectra of relative peaks with the aid of
the Varian Star Chromatography Workstation Version 6 software (Agilent Technologies) and a NIST
library of mass spectra (Gaithersburg, MD, USA). The percentage of each fatty acid was calculated
using the peak area of the samples corrected by the respective response factors. Analyses were carried
out in triplicate.
2.6. Statistical Analysis
All biological experimental analyses, extractions, and GC-MS analyses for each lipid sample were
sample were completed in triplicate. The obtained results were expressed as a mean value ± standard
deviation (SD). One-way analysis of variance (ANOVA) and the Tukey’s honest significant difference
(HSD) multiple comparison post-hoc test was used to determine the significant statistical differences
between the analyses (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Lipid Extraction and Fractionation of Beer, and Brewing Materials
The TL, TNL, and TPL content of the beer and brewing materials are shown in Table 1 expressed
in either mg/100g or g/100 g of TL, TNL, and TPL. The TNL and TPL are also expressed as a percentage
of the TL. The MG and BSG were both considerably low in TL, but the TPL accounted for a substantial
amount of the MG, of which just over half seems to be lost to the Brewer’s spent grain in the brewing
process. The largest amount of TL and TPL present in g/100 g of all samples was the PH, which was
significantly higher than all the other samples. Notably the SH had a considerably lower quantity of
TL and TPL than the PH, indicating that these lipids may have been extracted and diluted into the
wort. However, both the wort and the beer contained extremely low amounts of lipid, the majority of
which were polar lipids, results that are in accordance with previously published research [14,32,33].
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Table 1. The total lipid (TL) and the total polar lipids (TPL) content of beer and brewing by-product are
expressed as g/100 g and the total neutral lipid content (TNL) is expressed as mg/100 g. The TPL and
TNL are also expressed as a percentage of the TL (mean ± SD, n = 3).
Sample TL (g/100 g) TNL (mg/100 g) TNL (% TL) TPL (g/100 g) TPL (% TL)
MG 0.70 ± 0.10 a 100 ± 30 a 13.6 ± 2.9 c 0.52 ± 0.05 a 74.5 ± 3.5 b
BSG 1.05 ± 0.19 a 550 ± 110 b 52.6 ± 2.5 e 0.41 ± 0.09 a 38.9 ± 2.3 a
PH 14.17 ± 2.18 b 1630 ± 310 c 11.5 ± 3.7 bc 11.60 ± 1.68 b 79.4 ± 8.6 bc
SH 0.75 ± 0.06 a 160 ± 10 a 21.4 ± 3.0 d 0.55 ± 0.07 a 72.6 ± 4.1 b
Wort 0.03 ± 0.00 a 2.0 ± 1.0 a 5.4 ± 1.6 ab 0.03 ± 0.00 a 84.5 ± 8.9 bc
Beer 0.02 ± 0.00 a 0.3 ± 0.1 a 1.7 ± 0.4 a 0.02 ± 0.01 a 91.3 ± 2.7 c
a,b,c,d,e Different superscripts indicate significant differences among different lipid extracts within the same lipid class
(p < 0.05) when means are compared using a Tukey’s HSD multiple comparison test. Abbreviations: BSG = brewer’s
spent grain; MG = malted grain; PH = pelleted hops; SH = spent hops.
3.2. Gas Chromatography-Mass Spectrometry Analysis
While the general lipid composition of beer, wort, barley, and malts have been comprehensively
characterised by Bravi and colleagues [32–34], to the best of our knowledge the fatty acid profile of the
polar lipids specifically have not been previously reported. Therefore, the fatty acid profile of each TPL
extract were assessed by GC-MS (Table 2). Beer consists of many volatile and non-volatile compounds
that affect the beer flavour and bioactivities [14,32]. Many of the volatiles and fatty acids in beer are
synthesised by yeasts during fermentation, whereas others are derived from the raw materials [32].
Research demonstrates that the dominant fatty acids in the TL of barley grains, wort, and beer are
palmitic, stearic, cis-oleic, linoleic, and α-linolenic acids [35]. However, little is known about the fatty
acid profile of the polar lipid fractions of the raw materials, wort, or the beer itself.
In this study, the MG and BSG had similar TPL fatty acid profiles. Notably, there were statistically
significant differences between the MG and BSG in the percentage of palmitic and linoleic acids,
where both were higher percentages in the BSG than the MG TPL. Furthermore eicosenoic acid and
docosahexaenoic acids were present as a low percentage of the MG but were not detected in the BSG
TPL. Additionally, there were significant differences in the TPL fatty acid composition between the
MG, BSG, and the beer, namely the TPL fatty acids differed by a higher percentage of SFA and a
lower percentage of monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)
in the beer TPL in contrast to the MG and BSG. While the MUFA and PUFA were present in lower
amounts in the beer compared to the MG and BSG, arachidonic acid was present in the beer in notably
high amounts (4.9%) but was not present in the MG or BSG. Furthermore, myristic and stearic acid
were also present in a significantly high percentage of the beer TPL in contrast to the MG and BSG.
The MG and the wort also differ in composition, as there was a higher percentage of palmitic, stearic,
arachidonic, and eicosapentaenoic acids and a lower percentage of linoleic, arachidic, eicosenoic acid,
and docosahexaenoic acid with no phytochemicals detected in the MG, BSG, or wort TPL.
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Table 2. The fatty acid profile and volatile compounds detected in the total polar lipid (TPL) extracts of each sample are expressed as a percentage of the total volatile
components detected by GC-MS (mean ± SD, n = 3).
Fatty Acids Malt Grain Spent Grain Pelleted Hops Spent Hops Wort Beer
8:0 Caprylic acid ND ND 0.04 ± 0.01 b 0.02 ± 0.01 ab 0.01 ± 0.00 a ND
10:0 Capric acid ND ND 0.06 ± 0.00 b ND 0.01 ± 0.00 a 0.02 ± 0.01 a
12:0 Lauric acid 0.17 ± 0.02 d ND 0.02 ± 0.00 a 0.03 ± 0.01 a 0.09 ± 0.01 c 0.07 ± 0.00 b
12:1 cis-Lauroleic acid ND ND 0.05 ± 0.01 ND ND ND
14:0 Myristic acid 0.62 ± 0.06 b 0.69 ± 0.06 b 0.33 ± 0.05 a 1.04 ± 0.11 c 1.58 ± 0.04 d 1.55 ± 0.09 d
14:1 cis-Myristoleic acid ND 0.41 ± 0.11 ND ND ND ND
15:0 Pentadecylic acid 0.31 ± 0.04 a 0.22 ± 0.07 a 0.49 ± 0.14 b 0.25 ± 0.01 a 0.17 ± 0.02 a 0.16 ± 0.02 a
16:0 Palmitic acid 19.83 ± 0.93 a 27.86 ± 0.80 b 22.05 ± 1.23 a 30.38 ± 1.0 c 31.80 ± 0.60 c 32.34 ± 0.68 c
16:1 cis-Palmitoleic acid 0.39 ± 0.04 a 0.30 ± 0.12 a 2.35 ± 0.26 c 1.15 ± 0.15 b 0.60 ± 0.02 a 0.33 ± 0.21 a
17:0 Margaric acid 0.18 ± 0.02 a ND 1.24 ± 0.03 d 0.46 ± 0.03 c 0.24 ± 0.02 b 0.23 ± 0.01 ab
17:1 cis-Heptadecenoic acid 0.09 ± 0.01 a ND 0.75 ± 0.04 d 0.36 ± 0.03 c 0.20 ± 0.01 b 0.20 ± 0.03 b
18:0 Stearic acid 2.63 ± 0.62 ab 2.23 ± 0.25 a 2.85 ± 0.08 abc 3.85 ± 0.18 d 3.61 ± 0.09 cd 3.32 ± 0.10 bcd
18:1 c9 cis-Oleic acid 9.04 ± 0.19 d 8.81 ± 0.44 d 4.39 ± 0.11 a 6.67 ± 0.26 d 6.12 ± 0.24 bc 5.62 ± 0.18 b
18:1 t13 trans-Oleic acid 0.66 ± 0.02 a 1.01 ± 0.09 ab 1.27 ± 0.16 bc 1.82 ± 0.24 d 1.42 ± 0.09 c 1.26 ± 0.14 bc
18:2 c9, c12 Linoleic acid 56.67 ± 0.77 e 51.83 ± 1.59 d 25.46 ± 1.5 a 40.68 ± 0.34 b 44.78 ± 0.06 c 43.48 ± 1.55 bc
18:3 c6, c9, c12 γ-Linolenic acid ND ND 0.58 ± 0.02 b 0.12 ± 0.01 a ND ND
18:3 c9, c12, c15 α-Linolenic acid 6.80 ± 0.95 abc 5.87 ± 0.54 ab 23.42 ± 1.4 d 8.83 ± 0.92 c 7.72 ± 0.71 bc 5.13 ± 0.26 a
20:0 Arachidic acid 0.58 ± 0.10 ab 0.78 ± 0.17 bc 1.02 ± 0.04 c 0.48 ± 0.07 a ND ND
20:1 c13 Eicosenoic acid ND ND 0.25 ± 0.05 a 0.54 ± 0.04 c 0.39 ± 0.02 b ND
20:2 c11, c14 Eicosadienoic acid ND ND 1.00 ± 0.05 c 0.49 ± 0.07 b 0.27 ± 0.01 a 0.31 ± 0.04 a
20:4 c5, c8, c11, c14 Arachidonic acid ND ND ND ND 0.52 ± 0.06 4.93 ± 0.02
20:5 c5, c8, c11, c14, c17 Eicosapentaenoic acid ND ND 0.53 ± 0.01 b 0.16 ± 0.03 a 0.41 ± 0.10 b ND
22:0 Behenic acid 0.30 ± 0.04 a ND 1.32 ± 0.32 c 0.72 ± 0.13 b 0.41 ± 0.02 ab 0.29 ± 0.07 a
22:1 Erucic acid 0.32 ± 0.09 a ND 0.41 ± 0.06 a 0.34 ± 0.09 a ND ND
22:6 c4, c7, c10, c13, c16,
c19 Docosahexaenoic acid 0.47 ± 0.09
a ND 1.46 ± 0.17 b 0.43 ± 0.13 a ND ND
ΣSFA 24.43 ± 0.70 a 31.79 ± 0.94 b 29.40 ± 1.32 b 37.23 ± 0.91 c 37.94 ± 0.60 c 37.97 ± 0.54c
ΣMUFA 10.67 ± 0.14 c 10.53 ± 0.41 c 9.47 ± 0.48 b 10.86 ± 0.37 c 9.13 ± 0.21 b 7.42 ± 0.45 a
ΣPUFA 63.95 ± 1.53 c 57.69 ± 1.09 b 52.87 ± 2.66 a 50.71 ± 0.67 a 53.69 ± 0.60 a 53.75 ± 1.76 a
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Table 2. Cont.
Fatty Acids Malt Grain Spent Grain Pelleted Hops Spent Hops Wort Beer
Volatiles
Hexanedioic acid ND ND ND ND 0.28 ± 0.04 1.12 ± 0.21
Aromadendrene oxide ND ND 1.77 ± 0.39 0.11 ± 0.02 ND ND
2,4-Di-tert-butylphenol ND ND ND ND ND 0.12 ± 0.01
β-Caryophyllene ND ND 2.02 ± 0.37 b 0.37 ± 0.05 a ND 0.07 ± 0.01 a
2-Dodecanone ND ND 0.07 ± 0.05 0.04 ± 0.01 ND ND
Cubenol ND ND 0.24 ± 0.18 ND ND ND
Tau-Cadinol ND ND 0.14 ± 0.08 ND ND ND
Tau-Muurolol ND ND 0.29 ± 0.02 ND ND 0.08 ± 0.00
ΣVolatiles ND ND 8.90 ± 0.32 b 0.95 ± 0.32 a 0.28 ± 0.04 1.37 ± 0.22 a
a,b,c,d,e Mean values ± SD (n = 3), different letters in the same row indicate statistically significant differences between the lipid compositions when means are compared using Tukey’s HSD
multiple comparison test (p ≤ 0.05). Abbreviations: c = cis; MUFA = monounsaturated fatty acids; ND: non-detectable; PUFA = polyunsaturated fatty acids; SFA = saturated fatty acids;
t = trans.
Foods 2019, 8, 171 10 of 17
Another contributing factor to the fatty acid composition of beer is the hops. Hops are known for
their high concentrations of volatile components that can impart bitter flavours and aroma to the wort
and final product in the brewing process [36]. However, there is relatively little literature addressing
the fatty acid compositions of the TL or TPL of hops. In this study, there were significant differences
between the fatty acid compositions of the TPL of the PH and the SH. While the total percentage of
PUFA in the TPL of the PH and SH were similar, there was a significant increase in the percentage of
SFA and MUFA in the SH. However, this is most likely not due to an actual rise in the levels of these
fatty acids in the TPL, but may be due to the fact that the PH TPL extract contained a high amount
of volatile components that seemed to significantly reduce in the SH. Considering these levels of
volatile phytochemicals were not present in the wort or beer in any significant percentages, it is likely
that these volatiles were lost during the boiling of the wort, which has been documented previously
in studies [37]. Generally, there was a lower percentage of palmitoleic, margaric, and α-linolenic,
arachidic, eicosadienoic, docosahexaenoic acids in the SH in contrast to the PH, whereas there was a
significantly higher percentage of myristic, palmitic, stearic, cis-oleic, trans-oleic, and linoleic acids
in the SH in contrast to the PH. Furthermore, there was a high percentage of caryophyllene and
aromadendrene oxide in the PH TPL.
While the intention of this analysis was to assess the fatty acid profile of the TPL extract, volatile
phytochemicals and other constituents were also detected in the TPL extracts of beer, PH, and SH in
low percentages. The beer TPL extract contained the highest percentage of phytochemicals at 1.37%,
which can mainly be attributed to the detection of adipic acid (or hexanedioic acid). Other compounds
identified in the final beer TPL extract were β-caryophyllene, 2,4-Di-tert-butylphenol, and tau-muurolol
in low percentages. β-caryophyllene and other essential oils were also present in the PH TPL extracts,
including tau-muurolol, a cadinene sesquiterpenoid that is a plant metabolite, fungicide, and volatile
oil [38], which is commonly found in hops [39]. The PH also contains β-caryophyllene, a bicyclic
sesquiterpene that was also present in the beer and SH. β-caryophyllene is a characteristic essential oil
of hops that is usually in high abundance in comparison to other phytochemicals [36,40] and is the
most abundant phytochemical in the PH and SH TPL extract.
3.3. Platelet Aggregation Assay Analysis
The TL, TNL, and TPL of each extract were assessed for their ability to inhibit PAF and thrombin-induced
platelet aggregation in human PRP. The results of the platelet aggregometry assay for all lipid samples
are expressed as an IC50 value, which is the mass of the lipid sample in micrograms (µg) required
to inhibit half (50%) the maximum-reversible PAF/thrombin-induced platelet aggregation. The IC50
results for each extract tested against PAF-induced platelet aggregation are presented in Table 3. It is
clear from the data presented that overall the TL and TPL are the most bioactive fractions in the various
brewing-related extracts. Overall, the TNL extracts generally exhibited poor bioactivity. Notably
in the MG, the TNL was slightly more bioactive than the TL, but was less bioactive than the TPL.
Furthermore, the BSG TL had an exceedingly low IC50, and thus a higher anti-PAF effect, in comparison
to the relative effect of the TNL and TPL. It is not known why this may be the case and further research
is required to ascertain whether there may be synergistic effects between the compounds extracted
in the TL of the BSG. In terms of the hop extracts, TL, TNL, and TPL IC50 values were similar and
did not show any statistically significant differences between the PH and the SH. The wort and final
beer product were generally the most bioactive TL, TNL, and TPL extracts, although not statistically
significantly different from each other.
The IC50 results for each lipid extract assessed against thrombin-induced platelet aggregation are
presented in Table 4. Similarly to the results of the PAF-induced platelet aggregation assay, it is clear
that overall the TL and TPL are the most bioactive fractions in the various brewing-related extracts.
The IC50 values of the TNL of the MG, BSG, PH, and SH were high, indicating poor inhibition against
thrombin. However, the TNL IC50 values for the wort and beer were comparable to each other and
were considerably lower, and thus more effective against thrombin than the TNL extracts from all
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other sources. Like the TNL extracts, the TPL of the MG, BSG, PH, and SH were high, indicating poor
thrombin inhibition. However, the wort and the beer exhibited extremely low IC50 values that were
not statistically significantly different from each other. Notably, the TL extracts of the MG, BSG, PH,
and SH also possess considerable inhibitory properties against thrombin, although not as potent as the
beer or the wort.
Table 3. The in vitro biological activities of the total lipids (TL), total neutral lipids (TNL), and total
polar lipids (TPL) of the beer and brewing by-products against platelet-activating factor (PAF)-induced
human platelet aggregation, expressed as an IC50 in micrograms (µg) of the sample extract. The hPRP
concentration was approximately 500,000 platelets µL−1. The final concentration of PAF in the cuvette
was 2.6 × 10−8 M. All experimental analyses were carried out in triplicate (mean ± SD, n = 3).
Sample TL TNL TPL
MG 495 ± 105 b 298 ± 89 a 191 ± 58 ab
BSG 69 ± 33 a 610 ± 136 b 617 ± 184 c
PH 453 ± 109 b 1088 ± 172 c 473 ± 280 c
SH 519 ± 81 b 924 ± 166 c 436 ± 142 bc
Wort 70 ± 29 a 175 ± 61 a 58 ± 11 a
Beer 6.4 ± 4.5 a 248 ± 66 a 7.8 ± 3.9 a
a,b,c Different superscripts indicate significant differences among different lipid extracts within the same lipid class
(p < 0.05), when means are compared using ANOVA and Tukey’s HSD multiple comparison test. Abbreviations:
BSG = brewer’s spent grain; hPRP = human platelet-rich plasma; MG = malt grain PAF = platelet-activating factor;
PH = pelleted hops; SH = spent hops; TL = total lipids; TNL = total neutral lipids; TPL = total polar lipids.
Table 4. The in vitro biological activities of the total lipids (TL), total neutral lipids (TNL), and total
polar lipids (TPL) of the beer and brewing by-products against thrombin-induced human platelet
aggregation. Results are expressed as an IC50 in micrograms (µg) of each lipid extract. The hPRP
concentration was approximately 500,000 platelets µL−1. The final concentration of thrombin in the
cuvette was 0.1–1.0 mU/mL. All experimental analyses were carried out in triplicate (mean ± SD, n = 3).
Sample TL TNL TPL
MG 112 ± 21 b 433 ± 77 b 247 ± 39 b
BSG 87 ± 10 b 409 ± 30 b 203 ± 49 b
PH 221 ± 42 c 478 ± 97 b 207 ± 51 b
SH 155 ± 56 bc 572 ± 76 b 396 ± 62 c
Wort 10 ± 3.7 a 165 ± 61 a 24 ± 17 a
Beer 2.4 ± 0.9 a 206 ± 73 a 4.3 ± 3.0 a
a,b,c Different superscripts indicate significant differences among different lipid extracts within the same lipid class
(p < 0.05), when means are compared using ANOVA with Tukey’s HSD multiple comparison test. Abbreviations:
BSG = brewer’s spent grain; hPRP = human platelet-rich plasma; PAF = platelet-activating factor; MG = malt grain;
PH = pelleted hops; SH = spent hops; TL = total lipids; TNL = total neutral lipids; TPL = total polar lipids.
4. Discussion
Previous research has demonstrated that commercial ale, lager, and stout possess potent anti-PAF
activities as demonstrated through PAF-induced platelet aggregation assays [14]. Therefore, the aim
of this study was to assess the antithrombotic activities and fatty acid composition of brewing raw
materials, by-products, wort, and beer from a single production line in an active brewery.
In this study the TL, TNL, and TPL were extracted from the raw materials (MG and PH),
by-products (BSG and SH), wort, and Irish red ale, all originating from the same production line.
The raw materials used in beer production contain a significant amount of lipids, particularly from the
malted barley and hops. However, only trace amounts remain in the final beer product [19]. The lipid
content of the MG mix used as a raw material in this study was considerably low (0.7 g/100 g), where
other ale malts can possess higher lipid levels between 2.8–3.4 g/100 g as reported by Anness [41]. There
are several reasons why the lipid content of the MG was low in this study, including that the lipids of
barley tend to form complex interactions making them tightly bound to starch [18], thus making them
Foods 2019, 8, 171 12 of 17
difficult to extract. It is possible that much of the lipid was not efficiently extracted using the Bligh and
Dyer [29] method. This extraction method does not use harsh acid or heat treatments and therefore
does not efficiently extract all of the lipids but was chosen for this study as an efficient method for
extracting bioactive lipids against platelet aggregation. Indeed, studies have demonstrated a large
variation of lipid yield between different extraction procedures, including some being more efficient
than others for co-extracting non-lipid substances as part of the crude lipid content [42]. Other studies
have also acknowledged that barley lipids are poorly extractable without the use of hot alcoholic
extraction [43]. Therefore, further studies should consider the use of other extraction methods.
Notably, the BSG had a non-statistically significant higher lipid content than the malt, but a
statistically lower TPL content (~39% of the total lipids). This is in accordance with previous research
that estimates that 30% of the barley lipid content is lost during the germination of barley due to the
hydrolysis of triglycerides, which are subsequently metabolised [41].
The greatest amount of lipid extracted from any sample was the PH (14.7 g/100 g) with 79% being
polar compounds. In hops generally, there is a limited amount of fatty acids (1–2%) present [28].
However, the essential oil content of air-dried female hop flowers (strobiles) is generally around 0.5–3%,
whereas waxes and steroids are generally present in trace to high amounts (25%) [44]. Considering
that the hops used in this study were dried and pelleted, the oil and fatty acid content was highly
concentrated, thus explaining the high lipid content as per Table 1. The hops were added during
the boiling process to allow the essential oils present in the hops to contribute to beer flavour and
aroma [40]. However, much of the essential oils present in these bittering hops are highly volatile and
some are lost during the boiling process to evaporation [37], while any that remain are dispersed in the
wort, but may be filtered out during clarification of the wort. At the end of the boiling process, the SH
are collected within the trub. As demonstrated in Table 1, the SH contains low levels of lipids. This is
most likely due to the pelleted hops being dispersed and rehydrated within the wort and the loss of
some volatile compounds from the essential oils during the boiling process. Notably, there was a high
percentage of caryophyllene and aromadendrene oxide in the PH TPL. Aromadendrene oxide is an
oxygenated sesquiterpene that is considered an essential oil, which exhibits anticancer properties [45].
During the brewing process, a significant proportion of the lipid content is lost to the spent
grains [17]. Indeed, in this study the lipid content of the beer and wort were considerably low, but the
low beer TL is in accordance with previously published research [14,41]. The presence of lipids in beer
is generally considered as a negative proponent due to their effect on foam stabilisation and flavour.
Therefore, the reduction of lipid levels is actively reduced where possible through various parts of the
clarification processes used by breweries. The low lipid content of beer generally may also be due to
the fact that barley contains polar lipids and fatty acids that are closely associated with polysaccharides
that create amylose-lipid complexes that are difficult to fully extract [23]. Considering the high TL and
TPL content of the BSG, it is likely that this is the case and that these lipids are lost to the BSG.
The fatty acid composition of the TPL extracts of all the brewing ingredients, by-products, wort
and beer was determined. While the intention of the GC-MS analysis was to assess the fatty acid
profile of the TPL extract, volatile phytochemicals and other constituents were also detected in the TPL
extracts of the beer, PH, and SH in low but considerable percentages. The beer TPL extract contained
the highest percentage of phytochemicals at 1.37%, which can mainly be attributed to the detection
of adipic acid, an unusual non-volatile, alcohol soluble, dicarboxylic acid found sparsely in nature
but is used as a food additive (E355) as a firming or raising agent, which has tart flavour and is safe
for human consumption in low doses [46]. As it was not an intentional additive in the production of
the beer, it is not known where in the brewing process the adipic acid originates from or if it was a
contaminant as it was only found in the TPL of the wort and the final beer product.
Phenolic compounds play a significant role in aroma and flavour development in beer
production [47]. Present in beer, 2,4-Di-tert-butylphenol is a phenolic compound that is produced
by a variety of plants, but can also synthesised enzymatically by S. cerevisiae from organic acids [48].
Interestingly it is a bioactive compound with potential anticancer effects [49], antioxidant activities,
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and may be preventative against the neuroinflammatory effects of amyloid beta (Aβ) in animal models
of Alzheimer’s disease [50]. Considering some phenolic compounds have antiplatelet properties [51],
it is yet to be determined whether 2,4-Di-tert-butylphenol contributed to the antithrombotic activities
observed in this study. Tau-muurolol was also detected, which is a cadinene sesquiterpenoid that is a
plant metabolite, fungicide, and volatile oil [52] that was detected in the beer and PH TPL extracts.
β-caryophyllene, a bicyclic sesquiterpene was also present in the beer, PH, and SH. β-caryophyllene
is a characteristic essential oil of hops that is usually in high abundance in comparison to other
phytochemicals [36,40] and is the most abundant phytochemical in the PH and SH TPL extract.
Notably, caryophyllene compounds may possess anticancer, analgesic, antioxidant, antimicrobial,
and anti-inflammatory activities [53]. Indeed, caryophyllene molecules were present in abundance
in essential oil extracts from 25 species of plants that demonstrated anti-platelet activity against
adenosine diphosphate (ADP), arachidonic acid, and the thromboxane A2 agonist U46619-induced
platelet aggregation in guinea pig and rat plasma [54].
PAF and thrombin-induced platelet aggregation assays were used to assess the antithrombotic
activity of the TL, TNL, and TPL extracts of the brewing raw materials, by-products, wort, and beer.
Generally, the TPL extracts were the most potent against PAF-induced platelet aggregation. The TL
extracts exhibited considerable anti-PAF and anti-thrombin effects, but generally the TPL extracts
were more potent against PAF, whereas in the case of thrombin, the TL in cases were considerably
more antithrombotic than the TNL and moderately more potent that the TPL extracts. Considering,
the overall poorer inhibitory effects of both the TNL and TPL extracts of the MG, BSG, PH, and SH
against thrombin, the compounds present in the combined TL extract may induce synergistic effects
that improve the antithrombotic properties of these extracts, as has previously been demonstrated in
beer [14] and other extracts of natural origin marine extracts [55]. It can be suggested that coextracted
microconstituents such as phenolic compounds and phytochemicals with potential antithrombotic
activities may in part be responsible for these observations as previously demonstrated [51]. Indeed,
considering the BSG possessed potent anti-PAF and anti-thrombin activities, these by-products of the
brewing industry could potentially be used in the development of nutraceuticals or functional foods
and animal feeds, as has previously been demonstrated using by-products of the olive oil industry [56].
Indeed, BSG contains other significant bioactive microconstituents such as peptides and phenolic
compounds that exhibit antioxidant activity [26] that supports the need for further research into the
valorisation of BSG as a functional product for human health.
The beer and wort extracts were the most bioactive fractions against PAF and thrombin. While
not deemed statistically significantly different, the bioactivity of the TL and TPL of the wort seemed to
increase considerably following fermentation. Previous studies in dairy products have shown that
the fermentation process may play a role in the biosynthesis of functional antithrombotic lipids [57].
However, it has yet to be confirmed whether S. cerevisiae can indeed biosynthesise antithrombotic polar
lipids, but this study does demonstrate that yeasts may affect the fatty acid composition of the polar
lipids. Further structure activity relationship studies are required to confirm this notion.
As depicted in Table 2, there is a statistically significant increase in the percentage of polar lipids
bearing fatty acids arachidonic acid and eicosapentaenoic acid (EPA) in their structures as a result
or the wort fermentation. Various studies have demonstrated that polar lipids of natural origin that
bear these fatty acids in their structures along with stearic, cis-oleic, and linoleic acids, all of which
are present in abundance in the beer and wort TPL, exhibit potent antithrombotic properties against
PAF-induced platelet aggregation [9]. Similarly, the beer (red ale) TL and TPL IC50 values obtained in
this study were similar to those published for Smithwick’s red ale TL and TPL against PAF-induced
platelet aggregation using the same methods [27]. The fatty acid compositions of the wort and beer TPL
share structural resemblance to the classical PAF structure, which is generally composed of palmitic
(68%), stearic (27%), or oleic (4%) acids at the sn-1 position, with acetic acid esterified to the sn-2
position, and a phosphocholine group at the sn-3 position [58]. Juxtaposed, the most abundant fatty
acids of the TPL of the wort were palmitic (31.8%), stearic (3.6%), oleic (6.1%), and linoleic (44.8%)
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acids and the most abundant fatty acids present in the TPL of the beer were palmitic (32.3%), stearic
(3.3%), oleic (5.6%), and linoleic (43.4%) acids. Further research is required to confirm whether there is
structural homology between some polar lipids and PAF, which facilitates their binding to the PAF-R,
which may account for their potent biological actions against PAF.
In contrast to the wealth of evidence demonstrating that polar lipids can inhibit the biological
actions of PAF, there is little published research demonstrating the mechanisms for the antiplatelet
effects of food-derived polar lipids against thrombin-induced platelet aggregation. It seems that
the amphiphilic properties of these bioactive polar lipid moieties expedite their transfer from blood
lipoproteins to the membranes of circulating platelets. Thus such bioactive polar lipids can either directly
affect several platelet membrane receptors related to platelet activation (i.e. binding of polar lipids to
the PAF-R) [31] or indirectly affect these platelet receptors. Polar lipids may indirectly affect platelet
receptors through altering the microenvironment and polarisation of the phospholipid membrane,
which potentially alters the affinity of a ligand to a receptor relating to platelet activation, such as
thrombin [9,31,59,60]. However, further research is required to verify these potential mechanisms
and to discern the structures of these compounds, in order to fully elucidate the structure activity
relationships between bioactive polar lipid extracts and their overall antiplatelet effects.
5. Conclusions
The antithrombotic activities of lipid extracts from brewing raw materials, by-products, wort,
and beer were assessed. The most bioactive anti-PAF and anti-thrombin polar lipid extracts originated
from the wort and the final beer product. While not statistically significantly different, it is apparent
that fermentation of the wort may play a key role in increasing the anti-PAF bioactivity of polar
lipids extracted from beer. These findings are in accordance with previous studies demonstrating that
fermentation plays a key role in altering the bioactivity of anti-PAF polar lipids during milk fermentation.
Indeed, this research supports and furthers previously published research demonstrating the presence
of potent anti-PAF polar lipids in red ale. It was also observed that some phytochemicals and phenolic
compounds may contribute to antithrombotic properties of these lipid extracts. Furthermore, this is
the first study to demonstrate the anti-thrombin activities of beer polar lipids, but further research is
required to discern the exact structures and mechanisms responsible for these observations. Moreover,
it was determined that the BSG may be a suitable brewing industry by-product for valorisation as
potential nutraceuticals or functional foods for improved human cardiovascular health.
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